Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Cerus Corp Schedule 13G/A amendment: The Vanguard Group reports zero beneficial ownership of Cerus Corp common stock following an internal realignment. The filing states that, after the January 12, 2026 realignment, certain Vanguard subsidiaries will report holdings separately and Vanguard no longer is deemed to beneficially own shares held by those subsidiaries.
The filing is signed by Vanguard's Head of Global Fund Administration on March 26, 2026, and lists 0 shares and 0% ownership with no voting or dispositive power.
Soleus Capital Master Fund, L.P. and affiliated filers report beneficial ownership of 9,828,700 shares of Cerus Corporation common stock, representing 5.1% of the class based on 192,171,776 shares outstanding as of February 5, 2026.
The filing indicates shared voting and shared dispositive power over 9,828,700 shares among Soleus entities and Guy Levy. The filers state the shares are held directly by the Master Fund and include a standard disclaimer that affiliated entities and Mr. Levy disclaim beneficial ownership except for purposes of Section 13(d).
Cerus Corp Chief Legal Officer Chrystal Jensen reported an open-market sale of 113,008 shares of Common Stock on March 12, 2025. The weighted average sales price was $1.6572 per share, with individual trades ranging from $1.62 to $1.73 per share.
According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. Following the transactions, Jensen directly holds 946,131 shares of Cerus common stock.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an open‑market sale of 165,200 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. According to the filing, the sale was executed under an instruction intended to comply with Rule 10b5‑1 and was made to cover statutory tax withholding obligations and related brokerage fees arising from the vesting of restricted stock units, rather than as a discretionary sale. After this transaction, he directly holds 1,747,674 shares of Cerus common stock.
CERUS CORP President and CEO William Mariner Greenman reported an open-market sale of 447,757 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. The footnotes state the instruction was intended to comply with Rule 10b5-1 and was elected on the grant date to cover statutory tax withholding obligations and brokerage fees tied to the vesting of restricted stock units, so it was not a discretionary sale. After this transaction, he directly owned 4,998,493 shares of Cerus common stock.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1.
The filing explains the sale was elected on the date of grant to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of certain restricted stock units, and is not a discretionary sale by the CFO. After this transaction, he directly holds 1,040,551 shares of Cerus common stock.
CERUS CORP Chief Medical Officer Benjamin Richard J reported an open-market sale of 101,740 shares of Common Stock at a weighted average price of $1.6572 per share. After this transaction, he directly holds 777,361 shares.
According to the footnotes, these shares were sold under an instruction intended to comply with Rule 10b5-1 that was elected on the grant date to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. The sales occurred in multiple trades at prices ranging from $1.62 to $1.73 per share.
Cerus Corporation has appointed Vivek Jayaraman, currently Chief Operating Officer, as its next President and Chief Executive Officer effective July 1, 2026. On that date, current CEO and Board Chair William “Obi” Greenman will transition to the role of Executive Chairman, and Jayaraman will join the Board.
Under a new letter agreement effective March 11, 2026, Jayaraman will receive an annual base salary of $740,000, a target annual bonus opportunity of up to 80% of base salary starting in 2027, and will be eligible for equity incentives. These include a promotion equity award with a target value of $2,000,000 (75% time-based and 25% performance-based restricted stock units) and a one-time promotional performance-based award with a target value of $1,000,000. The number of shares for these awards will be based on the 30-day average closing price of Cerus common stock, but not less than $2.50 per share for calculation purposes.
If Jayaraman is terminated without cause or resigns for good reason, he may receive 12 months of base salary, a prorated annual bonus in certain cases, up to 12 months of COBRA premium support or equivalent cash payments, and full vesting of unvested time-based and performance-based restricted stock units, including in connection with a qualifying change in control.
CERUS CORP’s Chief Medical Officer Benjamin Richard J reported a mix of stock awards and planned sales. On March 5, 2026, he acquired 55,220 shares of common stock as a grant or award at no cost, increasing his direct holdings.
He then reported selling a total of 125,894 common shares in open-market transactions on March 5, 6, and 9, 2026 at weighted average prices of about $2.06, $2.01, and $1.88 per share. Footnotes state these sales were made under a Rule 10b5-1 trading plan and instructions elected on the grant date to cover statutory tax withholding and related fees, and are described as non-discretionary. After these transactions, he directly owns 879,101 Cerus common shares.
Cerus Corp’s chief financial officer Kevin Dennis Green reported a mix of stock awards and sales. On March 5, 2026, he acquired 63,854 shares of common stock in a grant or award at $0.00 per share, increasing his direct holdings.
On March 5 and 6, 2026, he sold a total of 83,021 shares of common stock in open‑market transactions at weighted average prices of about $2.06 and $2.01 per share. The filing notes that some sales were made under a Rule 10b5‑1 trading plan and that certain shares were sold pursuant to instructions elected at grant solely to cover statutory tax withholding and related brokerage fees, described as not discretionary sales.
After these transactions, Green directly owned 1,168,095 shares of Cerus common stock.